Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer.

Gynecologic Oncology
Kathleen N MooreJoyce F Liu

Abstract

This study investigated the safety and tolerability of lifastuzumab vedotin (DNIB0600A) (LIFA), an antibody-drug conjugate, in patients with recurrent platinum-sensitive ovarian cancer (PSOC). In this open-label, multicenter phase 1b study, LIFA was administered intravenously once every 3 weeks (Q3W) with starting dose 1.2 mg/kg in a 3 + 3 dose-escalation scheme. All patients received carboplatin at dose AUC 6 mg/mL·min (AUC6) Q3W for up to 6 cycles. Dose expansion cohorts were enrolled ± bevacizumab 15 mg/kg Q3W. Patients received LIFA at 1.2, 1.8, and 2.4 mg (n = 4, 5, and 20, respectively) with carboplatin. The maximum tolerated dose was not reached. The recommended phase 2 dose (RP2D) was LIFA 2.4 mg/kg + carboplatin AUC6 (cycles 1-6), with or without bevacizumab 15 mg/kg. Twelve patients received RP2D with bevacizumab. All patients experienced ≥1 adverse event (AE). The most common treatment-related AEs were neutropenia, peripheral neuropathy, thrombocytopenia, nausea, fatigue, anemia, diarrhea, vomiting, hypomagnesaemia, aspartate aminotransferase increased, alanine aminotransferase increased, and alopecia. Thirty-four (83%) patients experienced grade ≥ 3 AEs, the most frequent of which were neutropenia and thrombocytopen...Continue Reading

References

May 17, 2003·Pflügers Archiv : European journal of physiology·Heini MurerJürg Biber
Jun 5, 2003·Nature Biotechnology·Svetlana O DoroninaPeter D Senter
Sep 10, 2005·Nature Biotechnology·Anna M Wu, Peter D Senter
May 24, 2006·Seminars in Oncology·Jacobus Pfisterer, Jonathan A Ledermann
May 26, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric Pujade-LauraineAndreas du Bois
Jan 22, 2013·Bioanalysis·Surinder KaurMontserrat Carrasco-Triguero
May 28, 2014·Journal of Immunological Methods·Boris GorovitsJaya Goyal
Jul 15, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kedan LinPaul Polakis
Sep 22, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·David E GerberHoward A Burris

❮ Previous
Next ❯

Citations

Feb 10, 2021·Nature Reviews. Clinical Oncology·Joshua Z DragoSarat Chandarlapaty
Jun 15, 2021·Current Oncology Reports·David M O'Malley, Corinne A Calo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.